Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HIKMA Pharmaceuticals PLC Director's Dealing 2019

Mar 13, 2019

4841_dirs_2019-03-13_1391fbc7-eec6-49d7-8d10-2e8124177733.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7822S

Hikma Pharmaceuticals Plc

13 March 2019

Notification and public disclosure of transactions by persons discharging managerial responsibilities

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Executive Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Market purchase of 20,000 Ordinary Shares by Capital Investment & Brokerage / Jordan Ltd. Co for and on behalf of Said Darwazah.

c)

Price(s) and volume(s)

Price(s): £15.9166

Volume(s): 20,000

d)

Aggregated information

-       Volume

-       Price

20,000

£318,332.00

e)

Date of the transaction

13 March 2019

f)

Place of the transaction

London Stock Exchange (XLON)

Peter Speirs

Company Secretary, responsible for releasing this announcement

+44 (0) 20 7399 2760

13 March 2019

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHBXGDXRSBBGCX